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Motivation
Alternating Hemiplegia of Childhood (AHC) is a rare neurological condition char-
acterized by frequent episodes of temporary paralysis that often affect one side of
the body and in some cases both sides at once. A recent study established muta-
tions in the ATP1A3 gene, which codes for subunits of integral membrane proteins,
as the crucial cause of AHC [1]: the dysregulated excitability due tomembrane pro-
teins malfunctioning of neurons causes the pathology [1]. The challenge is to inte-
grate heterogeneous datasets such as drug-target interactions and target-pathway
associations to reveal new candidate drugs for this rare condition. To achieve this,
we collected lists of drugs “already in use” for AHC (or reference drugs), possible
helpful drugs according to medical doctors’ expertise target proteins of both drug
classes, and their associated molecular pathways in order to analyze the complete
framework. Then, we applied a generalizable network-based clustering approach
to the constructed network, postulating that drugs in the same cluster as the refer-
ence drugs can be considered as candidate novel drugs for the treatment of AHC.
Methods
We used Non-negative Matrix Tri-Factorization (NMTF) as a well-established co-
clustering technique in machine learning to cope with the heterogeneity of the
network [2]. NMTF is a well-developed method in data integration because of its
capacity to factorize any relation matrix between interconnected data types [2].
We considered three different datasets: drugs, proteins and pathways provided by
Dompé Pharmaceutics. We encoded the relationships between drugs and proteins
in a signed binary high-dimensional relation matrix, taking into account the ac-
tivation relationships as positive connections and the inhibition relationships as
negative connections. Proteins and pathways were related to each other according
to a binary high-dimensional relation matrix. Since NMTF is defined for positively
weighted graphs, we decided to split the drugs/proteins signed relationmatrix into
two matrices (respectively including activation and inhibition relationships) and
to apply NMTF to independently decompose each of the relation matrices into a
product of three non-negative low-dimensional matrices. The entries of such low-
dimensional matrices define the cluster assignation for drugs, proteins and path-
ways, respectively. In particular, the drug-cluster matrix, with rows representing
drugs and columns representing clusters, is used to place drug d into cluster k,
when k corresponds to the entry with the largest value in row d.
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Results
Figure 1A shows the results obtained considering the activation relationmatrix (pos-
itive drug/target interactions), for k=5 drug clusters (k is selected as the value for
which the clustering is most stable according to the dispersion coefficient [2]). Fig-
ure 1B shows results, where each drug is within a single cluster and reference drugs
are highlighted in red. Interestingly, some of the reference drugs are contained in
clusters 2 and 5 for positive interactions, and cluster 2 for negative interactions,
which contain drugswhose targets are highly related to ion channel transport path-
ways; therefore, drugs listed in the same clusters as the reference drugs can be
considered candidate drugs for the pathology, including Ifenprodil and Ketamine,
which therefore are examples of possible novel drug treatment for AHC.
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